KR20190018466A - 골관절염을 치료하기 위한 펩티드 - Google Patents

골관절염을 치료하기 위한 펩티드 Download PDF

Info

Publication number
KR20190018466A
KR20190018466A KR1020197000187A KR20197000187A KR20190018466A KR 20190018466 A KR20190018466 A KR 20190018466A KR 1020197000187 A KR1020197000187 A KR 1020197000187A KR 20197000187 A KR20197000187 A KR 20197000187A KR 20190018466 A KR20190018466 A KR 20190018466A
Authority
KR
South Korea
Prior art keywords
lys
ser
seq
asp
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197000187A
Other languages
English (en)
Korean (ko)
Inventor
클로드 카렐리
크리스텔르 베투
라파엘로 파올리니
Original Assignee
레귤라시스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 레귤라시스 filed Critical 레귤라시스
Publication of KR20190018466A publication Critical patent/KR20190018466A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020197000187A 2016-06-10 2017-06-09 골관절염을 치료하기 위한 펩티드 Ceased KR20190018466A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16174056.8 2016-06-10
EP16174056 2016-06-10
PCT/EP2017/064196 WO2017212057A1 (en) 2016-06-10 2017-06-09 Peptides for the treatment of osteoarthritis

Publications (1)

Publication Number Publication Date
KR20190018466A true KR20190018466A (ko) 2019-02-22

Family

ID=56132793

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197000187A Ceased KR20190018466A (ko) 2016-06-10 2017-06-09 골관절염을 치료하기 위한 펩티드

Country Status (12)

Country Link
US (1) US10813980B2 (cg-RX-API-DMAC7.html)
EP (1) EP3468582A1 (cg-RX-API-DMAC7.html)
JP (1) JP7010934B2 (cg-RX-API-DMAC7.html)
KR (1) KR20190018466A (cg-RX-API-DMAC7.html)
CN (1) CN109862905A (cg-RX-API-DMAC7.html)
AU (1) AU2017277747A1 (cg-RX-API-DMAC7.html)
BR (1) BR112018075613A2 (cg-RX-API-DMAC7.html)
CA (1) CA3026984A1 (cg-RX-API-DMAC7.html)
IL (1) IL263564B (cg-RX-API-DMAC7.html)
MA (1) MA45227A (cg-RX-API-DMAC7.html)
RU (1) RU2018145945A (cg-RX-API-DMAC7.html)
WO (1) WO2017212057A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230126458A (ko) 2022-02-23 2023-08-30 중앙대학교 산학협력단 졸참나무 잎 추출물을 유효성분으로 포함하는 골관절염 예방 또는 치료용 조성물

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108785661A (zh) * 2018-07-20 2018-11-13 深圳市第二人民医院 一种无副作用治疗退行性骨关节病的注射剂及其制备方法
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1208760B (it) * 1986-11-04 1989-07-10 Ind Farmaceutica Serono S P A Trattamento delle malattie infiammatorie articolari
FR2833012B1 (fr) 2001-12-04 2004-01-30 Centre Nat Rech Scient Peptides agonistes de l'hormone de croissance et leurs applications
US20040127402A1 (en) * 2002-12-27 2004-07-01 Vad Vijay B. Injectible composition and method for treating degenerative animal joints
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20070184015A1 (en) 2006-02-03 2007-08-09 Soonkap Hahn Novel PEGylation agent
WO2010105685A1 (en) 2009-03-19 2010-09-23 Universite Pierre Et Marie Curie Peptides for inhibiting igf-1
EP2502632B1 (en) 2009-11-18 2016-12-28 Asahi Kasei Pharma Corporation Preventative agent and/or therapeutic agent and/or exacerbation-suppressing agent for human knee osteoarthritis

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230126458A (ko) 2022-02-23 2023-08-30 중앙대학교 산학협력단 졸참나무 잎 추출물을 유효성분으로 포함하는 골관절염 예방 또는 치료용 조성물
KR20250135757A (ko) 2022-02-23 2025-09-15 중앙대학교 산학협력단 졸참나무 잎 추출물을 유효성분으로 포함하는 골관절염 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
RU2018145945A (ru) 2020-07-10
EP3468582A1 (en) 2019-04-17
WO2017212057A1 (en) 2017-12-14
IL263564B (en) 2021-07-29
BR112018075613A2 (pt) 2019-04-09
US10813980B2 (en) 2020-10-27
JP7010934B2 (ja) 2022-02-10
RU2018145945A3 (cg-RX-API-DMAC7.html) 2020-07-10
JP2019522046A (ja) 2019-08-08
US20190298808A1 (en) 2019-10-03
MA45227A (fr) 2019-04-17
IL263564A (en) 2019-02-03
CN109862905A (zh) 2019-06-07
CA3026984A1 (en) 2017-12-14
AU2017277747A1 (en) 2019-01-17

Similar Documents

Publication Publication Date Title
RU2525913C1 (ru) Новый пептид и его применение
ES2542509T3 (es) Una composición peptídica y un método de estimulación de la formación de cartílago
ES2688551T3 (es) Régimen de dosificación del compuesto FGF-18
CN102630157B (zh) 组合了黏性补充剂和成纤维细胞生长培养基的关节内应用的可注射组合物
ES3031633T3 (en) Annexin a1 n-terminal peptide formulations and methods
US20160122411A1 (en) Cartilage-binding fusion proteins
ES2794082T3 (es) Uso de dímeros de IL-22 en la fabricación de medicamentos para tratar la pancreatitis
CA2983977C (en) Short synthetic peptide for the treatment and/or prophylaxis of autoimmune and inflammatory disorders
PT2720710E (pt) Formulações liofilizadas de fgf-18
JP2023011938A (ja) ファーバー病を治療するための組成物及び方法
US10813980B2 (en) Methods for treating osteoarthritis by administering linked variants of growth hormone and somatostatin
US20250177490A1 (en) Compositions and methods for promoting islet viability and enhancing insulin secretion
EP3606547A1 (en) C4bp-based compounds for treating immunological diseases
EP2864353B1 (en) Selective cartilage therapy
WO2025150453A1 (ja) 変形性関節症の予防又は治療剤
ES2856930T3 (es) Composición para el tratamiento de afecciones articulares
US20050256039A1 (en) Novel fibroblast growth factors and methods of use thereof
CN110402149A (zh) 治疗组合物
AU2004238332A1 (en) Novel fibroblast growth factors and methods of use thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190103

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200605

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211130

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220613

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20211130

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I